cancer VBL Therapeutics raising $18.75m in Nasdaq offering

The Israeli drug development company's lead product is a targeted anti-cancer gene-therapy agent to treat a wide range of solid tumors.

Teva Photo: Reuters Teva recovery gains momentum

Despite no major announcements, Teva's share price has risen 23% since it hit a low point after the company's third quarter results.

ReWalk Photo: PR ReWalk raises $7.2m in secondary Nasdaq offering

Most of the money is designated for funding the company's upcoming clinical trial for stroke treatment.

Teva Photo: Tamar Matsafi US hedge funds reduce Teva exposure

Some financial institutions see an opportunity in Teva's low share price and have increased their holdings in the company.

George Horesh Photos: PR and Tamar Matsafi George Horesh mulls buying Ra'anana land back from Teva

If Horesh exercises his option, he is likely to lease the land to Amdocs, which wants to buy it.

Health Photo: Shutterstock ASAP Creative Medical cybersecurity co Medigate raises $5.35m

The Tel Aviv based digital health company secures the use of the millions of connected medical devices on healthcare provider networks.

Teva Photo: Reuters Allergan begins selling 10% Teva stake to JP Morgan

Allergan has attached its shares in Teva in favor of the JP Morgan bank as security for a one-year loan of unspecified size.

Amir London Photo: Einat Levron Kamada heading for $100m revenue in 2017

Kamada CEO Amir London is expressing confidence, with the company publishing guidance of $116-120 million in revenue for 2018.

Kadimastem CEO Yossi Ben-Yosef, photo: Studio-One Kadimastem down 90% in 2017

Shares in Kadimastem, which is developing a stem-cell based therapy for ALS, dropped 28% in one day.

Kamada Kamada agrees 3 new directors with Brosh Capital

Activist fund Brosh Capital owns 7.2% of Kamada.

Dalton Conley Photo: PR "Genetic inequality is increasing"

Princeton University's Prof. Dalton Conley tells "Globes" that understanding the interaction between genetics and environment will start a social revolution.

CollPlant Bio-Ink Photo: PR Regenerative medicine co CollPlant raises $7.4m

The company announced last month that it is on the way to developing a 3D-printed orthopaedic implant.

TASE TASE unfazed by Mylan delisting

The Tel Aviv 35 Index will more faithfully reflect the Israeli economy.

New-Pharm  photo: PR Nisanov Brothers buys eleven New-Pharm branches

The sale paves the way for completion of the larger deal whereby Shufersal is buying New-Pharm from Hamashbir. 

Mylan chairman Robert J. Coury Mylan to delist from TASE

The generic drug company's move is a blow to the Tel Aviv Stock Exchange's recovery prospects.

Teva  photo: Reuters Poalim IBI: Teva must raise capital

Analyst Steven Tepper tells "Globes" that if Teva wants to stay independent, it needs capital, or it will be exposed to a takeover.

Prof. Zelig Eshar Photo: Shlomi Yosef Israeli professors fight for Kite Pharma sale spoils

Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.

Arie Belldegrun Photo: PR "Chemotherapy will become just a bad memory"

More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.

Mori Arkin, Uri Geiger photos: Tamar Matsafi, Eyal Izhar Accelmed fattening Cogentix for sale

Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.

Essence Group  photo: PR Smart home means safe home for seniors

Israeli company Essence develops products that enable people to keep living at home in old age.

Prof Michal Schwartz photo: Rami Zarnegar "Lady Globes" Woman of the Year: Prof. Michal Schwartz

The Weizmann Institute researcher's groundbreaking research on Alzheimer's Disease is leading to new treatment for it.

Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017